CorMedix
86 Summit Avenue
Suite 301
Summit
New Jersey
07901
United States
Tel: 908-517-9500
Fax: 908-522-9199
Website: http://www.cormedix.com/
206 articles about CorMedix
-
CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/12/2024
CorMedix Inc. announced financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its business.
-
CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024
3/6/2024
CorMedix Inc. today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2023, before the market opens on Tuesday, March 12, 2024, and will host a corporate update conference call at 8:30am Eastern Time.
-
CorMedix Inc. Announces Commercial and Operational Updates
1/8/2024
CorMedix Inc. announced several commercial and operational updates related to its business and anticipated launch of DefenCath®.
-
CorMedix Inc. Announces Appointment of Chief Legal Officer
12/15/2023
CorMedix Inc. (Nasdaq: CRMD) today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023.
-
Approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs, CorMedix’s DefenCath reduces the incidence of catheter-related bloodstream infections in adult hemodialysis patients.
-
CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients
11/15/2023
CorMedix Inc. (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has approved DefenCath® (taurolidine and heparin) catheter lock solution (CLS) to reduce the incidence of catheter-related bloodstream infections (CRBSIs) for the limited population of adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC).
-
CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Updatee
11/14/2023
CorMedix Inc. announced financial results for the third quarter and nine months ended September 30, 2023 and provided an update on recent business events.
-
Over the next two weeks, the FDA is set to decide on New Drug Applications from Pacira, CorMedix and Aldeyra and hold an advisory committee meeting for two overdue confirmatory trials from Acrotech.
-
CorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023
11/2/2023
CorMedix Inc. today announced that it will report its financial results for the third quarter ended September 30, 2023, after the market closes on Tuesday, November 14, 2023, and will host a corporate update conference call at 4:30pm Eastern Time.
-
CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
10/11/2023
CorMedix Inc. today announced that an abstract has been accepted for presentation at the IDWeek 2023 meeting being held in Boston, Massachusetts, October 11 – 15.
-
CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
9/26/2023
CorMedix Inc. (Nasdaq: CRMD) today announced that management will be giving a company presentation at the Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 26 – 28, 2023.
-
CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology
9/8/2023
CorMedix Inc. today announced the publication of its Phase 3 LOCK IT-100 study results in the Clinical Journal of the American Society of Nephrology, or CJASN.
-
CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
9/6/2023
CorMedix Inc. today announced that management will be giving a company presentation at the H.C. Wainwright Global Investment Conference being held in New York City on September 11 – 13, 2023.
-
CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath
8/30/2023
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,738,120 with claims directed to the composition of a catheter lock solution for preventing infection and reduced blood flow in central venous catheters.
-
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
8/8/2023
CorMedix Inc. today announced financial results for the second quarter and six months ended June 30, 2023 and provided an update on recent business events.
-
CorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023
7/26/2023
CorMedix Inc. today announced that it will report its financial results for the second quarter ended June 30, 2023, before the market opens on Tuesday, August 8, 2023, and will host a corporate update conference call at 8:30am Eastern Time.
-
CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants
6/29/2023
CorMedix Inc. announced the pricing of its previously announced underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $4.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 2,500,625 shares of its common stock at a price of $3.999 per pre-funded warrant.
-
CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
6/28/2023
CorMedix Inc. announced that it intends to offer and sell shares of its common stock, and in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering.
-
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath - June 21, 2023
6/21/2023
CorMedix Inc. today announced that the resubmission of the New Drug Application (NDA) for DefenCath has been accepted for filing by the U.S. Food and Drug Administration (FDA).
-
Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream Infections
6/15/2023
CorMedix Inc. announced its first-of-kind strategic initiative with Boston Medical Center to enhance patient safety and reduce health disparities in structurally marginalized populations at risk for bloodstream infections while undergoing dialysis.